Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome
Michel A. Steiner, Carla Sciarretta, Anne Pasquali, et al.
Frontiers in Pharmacology (2013) Vol. 4
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 72
Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?
Shaun Yon‐Seng Khoo, Robyn M. Brown
CNS Drugs (2014) Vol. 28, Iss. 8, pp. 713-730
Open Access | Times Cited: 58
Orexin/Hypocretin System: Role in Food and Drug Overconsumption
Jessica R. Barson, Sarah F. Leibowitz
International review of neurobiology (2017), pp. 199-237
Open Access | Times Cited: 56
Differential Roles of Each Orexin Receptor Signaling in Obesity
Miyo Kakizaki, Yousuke Tsuneoka, Kenkichi Takase, et al.
iScience (2019) Vol. 20, pp. 1-13
Open Access | Times Cited: 46
Targeting orexin receptors: Recent advances in the development of subtype selective or dual ligands for the treatment of neuropsychiatric disorders
Alessandro Bonifazi, Fabio Del Bello, Gianfabio Giorgioni, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 5, pp. 1607-1667
Closed Access | Times Cited: 13
Heat-killed Bifidobacterium animalis subsp. Lactis CECT 8145 increases lean mass and ameliorates metabolic syndrome in cafeteria-fed obese rats
Antoni Caimari, Josep M Del Bas-Prior, Noemí Boqué, et al.
Journal of Functional Foods (2017) Vol. 38, pp. 251-263
Closed Access | Times Cited: 39
Manipulating the Circadian and Sleep Cycles to Protect Against Metabolic Disease
Kazunari Nohara, Seung‐Hee Yoo, Zheng Chen
Frontiers in Endocrinology (2015) Vol. 6
Open Access | Times Cited: 38
Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs
Anil Kumar, Priyanka Chanana, Supriti Choudhary
Pharmacological Reports (2015) Vol. 68, Iss. 2, pp. 231-242
Closed Access | Times Cited: 35
Sleep Control, GPCRs, and Glucose Metabolism
Hiroshi Tsuneki, Toshiyasu Sasaoka, Takeshi Sakurai
Trends in Endocrinology and Metabolism (2016) Vol. 27, Iss. 9, pp. 633-642
Closed Access | Times Cited: 32
Orexins (hypocretins): The intersection between homeostatic and hedonic feeding
Muthmainah Muthmainah, Andrea Gogos, Priya Sumithran, et al.
Journal of Neurochemistry (2021) Vol. 157, Iss. 5, pp. 1473-1494
Open Access | Times Cited: 23
Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior
Ewa Bojanowska, Joanna Ciosek
Current Neuropharmacology (2015) Vol. 14, Iss. 2, pp. 118-142
Open Access | Times Cited: 32
Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat
Mirza Irfan Beig, Bruno W. Dampney, Pascal Carrive
Neuropharmacology (2014) Vol. 89, pp. 146-156
Open Access | Times Cited: 30
Cherry consumption out of season alters lipid and glucose homeostasis in normoweight and cafeteria-fed obese Fischer 344 rats
Roger Mariné-Casadó, Cristina Domenech-Coca, Josep M Del Bas-Prior, et al.
The Journal of Nutritional Biochemistry (2018) Vol. 63, pp. 72-86
Closed Access | Times Cited: 18
Generation of TALEN-mediated FH knockout rat model
Dandan Yu, Yali Zhong, Xiaoran Li, et al.
Oncotarget (2016) Vol. 7, Iss. 38, pp. 61656-61669
Open Access | Times Cited: 14
CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity
María José Franco-Tormo, Mireille Salas-Crisóstomo, Nuno Rocha, et al.
Journal of Molecular Neuroscience (2018) Vol. 65, Iss. 1, pp. 10-16
Closed Access | Times Cited: 12
Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus
Mirza Irfan Beig, Jouji Horiuchi, R.A.L. Dampney, et al.
Clinical and Experimental Pharmacology and Physiology (2015) Vol. 42, Iss. 10, pp. 1059-1067
Closed Access | Times Cited: 9
Effect of Angiotensin(1-7) on Heart Function in an Experimental Rat Model of Obesity
Katja Blanke, Franziska Schlegel, Walter Raasch, et al.
Frontiers in Physiology (2015) Vol. 6
Open Access | Times Cited: 9
Chronotherapeutic effect of orexin antagonists on glucose metabolism in diabetic mice
Kanta Kon, Hiroshi Tsuneki, Hisakatsu Ito, et al.
Journal of Endocrinology (2019) Vol. 243, Iss. 1, pp. 59-72
Open Access | Times Cited: 7
TALEN‐mediated generation of Nkx3.1 knockout rat model
Ji Min Lee, Ukjin Kim, Hyokyung Yang, et al.
The Prostate (2020) Vol. 81, Iss. 3, pp. 182-193
Closed Access | Times Cited: 6
Opportunities and perspectives for developing orexin receptor antagonists
Michel A. Steiner, Christopher J. Winrow
Frontiers in Neuroscience (2014) Vol. 8
Open Access | Times Cited: 4
Orexin and Metabolism
Hiromasa Funato
Springer eBooks (2015), pp. 363-380
Closed Access | Times Cited: 4
Orexin receptors in GtoPdb v.2021.3
Paul J. Coleman, Luı́s de Lecea, Anthony L. Gotter, et al.
IUPHAR/BPS Guide to Pharmacology CITE (2021) Vol. 2021, Iss. 3
Open Access | Times Cited: 4
Privileged heterocycles: bioactivity and synthesis of 1,9-diazaspiro[5.5]undecane-containing compounds
Daniel Blanco‐Ania, Rik Heus, Floris P. J. T. Rutjes
Chemistry of Heterocyclic Compounds (2017) Vol. 53, Iss. 8, pp. 827-845
Open Access | Times Cited: 3
Orexin receptors in GtoPdb v.2023.1
Gary Aston‐Jones, Pascal Bonaventure, Paul J. Coleman, et al.
IUPHAR/BPS Guide to Pharmacology CITE (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 1
Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934)
Christoph Boss, Catherine Roch
Expert Opinion on Therapeutic Patents (2015) Vol. 26, Iss. 3, pp. 409-415
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top